
Results Over 50,000 unique patients were included, with median age 30.5; patients were 48% White, 47% men who have sex with men (MSM), and 7% transwomen. Overall, there were 14.6 patients on PrEP for each incident HIV infection (PrEP:Need). PrEP:Need was 24.5 among White patients, compared to 6.6 among Black patients. PrEP:Need was low for Medicaid/Medicare patients (7.9), transwomen (10.0), and particularly Black transwomen (4.6). Low PrEP:Need ratios were usually driven by low Identification:Need ratios, with large differences: among MSM, 23.2 patients were indicated for PrEP per incident infection compared to 7.2 among transwomen. Uptake, measured by PrEP:Identification ratios, were lowest among patients without insurance and highest among those with private insurance.

Conclusion We found high variation in PrEP:Need ratios across race, gender, and insurance status. This may be due to a poor fit between current PrEP indications and actual HIV incidence in key populations; there may also be gaps in patient-provider communication and documentation of PrEP indications in certain populations. We also found evidence of barriers to uptake, particularly related to insurance status. We will discuss ways to improve PrEP detection and uptake, which attendees can apply to their practice.

Disclosure No significant relationships.

Q010.3 HIGH CURABLE STI PREVALENCE AND INCIDENCE AMONG YOUNG AFRICAN WOMEN INITIATING PREP IN HPTN 082

1Sinead Delany-Morettive*, 2Nyaradzo Mgodi, 3Linda-Gail Bekker, 4Jared Baeten, 5Subash Pathak, 6Deborah Donnelly, 7Denni Lennon, 8Scott Rose, 9Koolpilo Makgamaathe, 2Sheetal Kassim, 3Storla Miusika, 4Heather Noble, 5Akedes Adayeye, 6Connie Celum, 1University of the Witwatersrand, Wits RHI, Johannesburg, South Africa; 2University of Zimbabwe, College of Health Sciences Clinical Trials Unit, Harare, Zimbabwe; 3University of Cape Town, Infectious Diseases, Cape Town, South Africa; 4University of Washington, Medicine, Global Health, Epidemiology, Seattle, USA; 5Fred Hutchinson Cancer Research Centre, Seattle, USA; 6Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, USA; 7FHI 360, 8FHI 360, HIV Prevention Trials Network, Durham, USA; 9The Desmond Tutu HIV Centre, Cape Town, South Africa; 10National Institutes of Allergy and Infectious Diseases, Division of AIDS, Rockville, USA; 11University of Washington, Seattle, USA

Background African women face overlapping HIV and STI risks. PrEP programs among men who have sex with men have seen high STI incidence, but few data from African women taking PrEP are available.

Methods HPTN 082 was conducted in Cape Town, Johannesburg (South Africa) and Harare (Zimbabwe) to evaluate uptake and adherence to daily oral PrEP in young African women. Sexually active HIV-negative women ages 16–25 were enrolled. Enrollment vaginal swabs were tested for gonorrhlea (GC) and chlamydia (CT) by nucleic acid amplification, and trichomonas (TV) by rapid test. Syphilis serology was assessed. All women with positive test results received treatment. Repeat testing was conducted at 6 and 12 months.

Results Of the 412 women who initiated PrEP, median age was 21 years, 84% reported a primary sex partner and a median of 4 vaginal sex acts (IQR 2,8) in the prior month; 35% reported that they never or rarely used condoms. At enrollment 29% of women had CT, 8% GC, 7% TV and 2% reactive syphilis serology. STI incidence was 29.6 per 100 person-years (py) for CT (95% CI 24.3, 35.4), 11.8 per 100 py for GC (95% CI 8.7, 15.7), and 7.1 per 100 py for TV
(95% CI 4.7, 10.2). The majority of incident STIs were new infections: 79 of 119 CT infections, 41 of 48 GC infections, and 23 of 29 TV infections diagnosed were in women who did not have these infections at enrollment. The majority of these infections were asymptomatic.

Conclusion The prevalence and incidence of treatable STIs were high among young African women initiating PrEP. Diagnostic STI testing is important and innovative strategies that reduce STI acquisition, complications, and their potential impact on future fertility, need evaluation within the context of PrEP services where currently syndromic STI management is the standard of care.

Disclosure No significant relationships.

**010.4 SCALING UP HCV SCREENING AND TREATMENT FOR ELIMINATING HCV AMONG MSM IN UK IN THE ERA OF HIV PRE-EXPOSURE PROPHYLAXIS**

1Louis MacGregor*, 2Monica Desai, 3Natasha Martin, 1Jane Nicholls, 4Ford Hickson, 5Peter Weatherburn, 6Matthew Hickman, 7Peter Vickerman. 1University of Manchester, Manchester, UK; 2University of California San Diego, San Diego, USA; 3London School of Hygiene and Tropical Medicine, London, UK; 4London School of Hygiene and Tropical Medicine, Sigma Research, London, UK; 5London School of Hygiene and Tropical Medicine, Center for Child And Community Health Research, Baltimore, USA; 6Johns Hopkins University School of Medicine, School of Medicine, The John G. Bartlett Specialty Practice, Baltimore, USA; 7Baltimore City Health Department, Sexual Health/STD Clinics, Baltimore, USA; 8The Johns Hopkins Hospital, Harriet Lane Clinic, Baltimore, USA; 9University of Maryland School of Medicine, Department of Pediatrics, Baltimore, USA; 10The Johns Hopkins University School of Nursing, Reach Initiative, Baltimore, USA; 11Baltimore City Health Department, Baltimore, USA

10.1136/sextrans-2019-sti.161

**Background** Routine HIV pre-exposure prophylaxis (PrEP) and HIV care appointments provide opportunities for screening men who have sex with men (MSM) for hepatitis C virus infection (HCV). However, levels of screening required for achieving the WHO elimination target of reducing HCV incidence by 90% by 2030 among all MSM are unknown.

**Methods** An HCV/HIV transmission model was calibrated to UK prevalence of HIV (5-9%) and chronic HCV infection among HIV-positive MSM (10-0%). Assuming 12.5% coverage of PrEP among HIV-negative MSM, we evaluated the impact on HCV incidence (2018–2030) of HCV screening every 12/6/3-months (and completing treatment within 6 months of diagnosis) in PrEP users and/or HIV-diagnosed MSM. We then estimated the additional screening required among HIV-negative non-PrEP users to achieve a 90% reduction in overall incidence by 2025/2030. The effect of a 50% reduction in overall care use among PrEP users (risk compensation) was estimated.

**Results** Without risk compensation, PrEP scale-up decreases HCV incidence by 9-5% by 2030, whereas it increases by 26-5% with risk compensation. Screening and treating PrEP users for HCV every 12/6/3-months decreases HCV incidence by 41/46/48%, respectively, increasing to 74/81/83% if HIV-diagnosed MSM are also screened at the same frequencies. Risk compensation reduces these latter projections by <5%, To achieve a 90% reduction in HCV incidence by 2030 (values in brackets are with risk compensation), HIV-negative MSM not on PrEP require screening every 5-2 (4-5) years if MSM on PrEP and HIV-diagnosed MSM are screened every 6-months, decreasing to every 2-6 (2-3) years for the 2025 target. For 2.5% PrEP coverage, the 2030 HCV elimination target may be reached without screening HIV-negative MSM not on PrEP.

**Conclusion** Increased screening of all MSM (particularly HIV-diagnosed MSM and MSM on PrEP) is required to achieve the WHO HCV-elimination targets for MSM in the UK.

**Disclosure** No significant relationships.

**010.5 PATTERNS OF HIV PRE-EXPOSURE PROPHYLAXIS CARE ONE YEAR AFTER INITIATING PREP, BALTIMORE CITY, MARYLAND 2015–2018**

1Linlun Wu*, 2Christina Schumacher, 3Aurana Chandran, 4Emil Fields, 5Maisha Davis, 6Patrick Ryscavage, 7Joyce Jones, 8Kathleen Page, 9Renata Arrington-Sanders, 10Vicki Tepper, 11Jason Farley, 12Adena Greenbaum, 13Jenny Jennings. 1Johns Hopkins School of Medicine, Center for Child And Community Health Research, Baltimore, USA; 2Johns Hopkins University School of Medicine, Center for Child and Community Health Research (CCHR), Baltimore, USA; 3Chase Brexton Health Care, Baltimore, USA; 4University of Maryland Midtown Campus, Division Of Infectious Diseases, Baltimore, USA; 5Johns Hopkins University School of Medicine, The John G. Bartlett Specialty Practice, Baltimore, USA; 6Baltimore City Health Department, Sexual Health/STD Clinics, Baltimore, USA; 7The Johns Hopkins Hospital, Harriet Lane Clinic, Baltimore, USA; 8University of Maryland School of Medicine, Department of Pediatrics, Baltimore, USA; 9The Johns Hopkins University School of Nursing, Reach Initiative, Baltimore, USA; 10The Johns Hopkins School of Medicine, Family Medicine, Baltimore, USA; 11Baltimore City Health Department, Baltimore, USA

10.1136/sextrans-2019-sti.162

**Background** Persistent HIV pre-exposure prophylaxis (PrEP) use is critical to preventing HIV acquisition. U.S. Centers for Disease Control and Prevention (CDC) recommends quarterly clinical evaluation for individuals using PrEP. Individual-level adherence to quarterly PrEP-care visits is largely unknown. Our objective was to describe patterns of quarterly PrEP-care visit attendance among individuals enrolled in a large demonstration project to increase PrEP delivery in Baltimore City, Maryland.

**Methods** The project was a collaboration between a city health department, an academic evaluation partner, 6 clinical sites and one community based organization (CBO). Demographic and quarterly PrEP-care visit information from individuals initiating PrEP between October 1, 2015 and August 31, 2017 was abstracted from medical records using standardized forms. Participants were followed for one year. PrEP-care was categorized as ‘Persistent’ (attending all quarterly PrEP-care visits), ‘Episodic’ (missing ≥ 1 PrEP-care visit and re-engaging PrEP-care visit), or ‘Discontinued’ (lost to follow-up after missing ≥ 1 PrEP-care visit).

**Results** During the study period, 333 individuals initiated PrEP, among whom 52.9% (176) were Black/African-American, 82.3% (274) gay/lesbian male, 73.6% (245) men who have sex with men (MSM), and 47.7% (159) aged 25–24 years. 9.0% (30), 40.5% (135), and 50.5% (168) were persistent, episodic and discontinued PrEP-care users, respectively. Over half (51.1%, 69/135) of episodic users missed the first quarterly visit; mean time to PrEP re-engaging was 6.3 months (SD: 2.18). About half (45.2%, 76/168) of those discontinuing PrEP-care did so within 3-months.

**Conclusion** Over one year, < 10% of individuals initiating PrEP were persistently in PrEP-care, and half discontinued PrEP-care completely. This suggests PrEP’s effectiveness in